Organon's (NYSE:OGN) Earnings Are Weaker Than They Seem
Despite announcing strong earnings, Organon & Co.'s ( NYSE:OGN ) stock was sluggish. We did some digging and found ...
Philippine Daily Inquirer1d
Organon launches her health finder to improve access to women’s reproductive healthcare
Organon Philippines, a women’s health company, recently unveiled its Her Health Finder, an online tool that aims to empower ...
JD Supra2d
FDA Accepts BLA for Shanghai Henlius Biotech’s and Organon’s HLX14, a Denosumab Biosimilar
On October 30, 2024, Shanghai Henlius Biotech and Organon announced that the FDA has accepted the Biologic License Application (BLA) for HLX14, a proposed biosimilar to PROLIA/XGEVA (denosumab). In ...
中国日报网2d
CIIE opens up infinite possibilities for pharma, medical device industry
The booth of Lundbeck at the ongoing 7th CIIE in Shanghai. [Photo/chinadaily.com.cn] US-based pharmaceutical company Organon ...
Looking Into Organon's Recent Short Interest
Organon's OGN short percent of float has risen 28.4% since its last report. The company recently reported that it has 12.53 ...
International Assets Investment Management LLC Acquires 18,111 Shares of Organon & Co. (NYSE:OGN)
International Assets Investment Management LLC increased its holdings in Organon & Co. (NYSE:OGN – Free Report) by 1,851.8% in the third quarter, HoldingsChannel.com reports. The institutional ...
bovnews3d
What’s Causing Organon & Co (OGN) Stock’s -19.31% Drop Over the Last Six Months?
On Tuesday, Organon & Co (OGN) stock saw a decline, ending the day at $16.46 which represents a decrease of $-0.46 or -2.72% from the prior close of $16.92. The stock opened at $16.74 and touched a ...
pulmonologyadvisor3d
FDA Extends Review of Tapinarof Cream for Atopic Dermatitis
The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.
Organon reports FDA extension of target action date of review of Vtama sNDA
Organon (OGN) announced that the FDA extended by three months the target action date of its review of the supplemental New Drug Application, or ...
ENDPOINTS NEWS4d
Syn­dax inks a $350M roy­al­ty deal; FDA push­es back de­ci­sion on Organon’s eczema drug
Syndax Pharmaceuticals’ $350M deal with Royalty Pharma: The agreement is based on US sales of Niktimvo, Syndax’s graft-versus-host disease ...
Organon: FDA Extends Vtama Atopic-Dermatitis Review to March
Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...
centerforbiosimilars4d
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as ...